Biotech
Commented by Fabian Lorenz on May 29th, 2026 | 09:40 CEST
A 4,000% gain is not enough? SanDisk, BioNTech, and Standard Uranium
60% in one month, 600% in six months, and 4,000% in one year. Yet there is still no sign of a major correction in SanDisk's stock. Even now, analysts are still raising their price targets significantly and joining the bulls' camp. In contrast, the uranium sector is currently on the sidelines. This offers a chance for contrarian investors. After all, it can really only be a matter of time before the industry is rediscovered as an AI winner. One exciting stock is Standard Uranium. The CEO recently made a strong impression at an investor conference. And what about BioNTech? Investors are disappointed, but analysts are positive. Can the biotech company provide new momentum starting today with new data from its oncology pipeline?
Read
Commented by Fabian Lorenz on May 26th, 2026 | 07:30 CEST
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock?
Investor sentiment around Novo Nordisk is improving. Shares of the Danish pharmaceutical giant appear to be breaking out of the downtrend that began in the summer of 2024, with investors responding positively to recent developments. At Vidac Pharma, the latest announcement seems to have gone largely unnoticed. Yet it could mark the beginning of interest from strategic investors. There is even speculation about a potential full takeover of the oncology specialist. With a market capitalization of only around EUR 33 million, any acquisition would likely require a substantial premium. While investors may be knocking on Vidac's door, sentiment toward BioNTech has deteriorated. The company's founding couple is stepping down, and locations are being closed. And now analysts are also questioning the quality of the company's product pipeline.
Read
Commented by Fabian Lorenz on May 26th, 2026 | 07:15 CEST
+36% in Just a Few Weeks! TeamViewer Impresses Mercedes Formula 1 Team! Will X Corp and BioNxt Solutions Follow?
A 36% gain in just six weeks! Was the market completely wrong about TeamViewer? Is the German software company not an AI loser after all, but instead a potential winner? While it is still too early for a definitive conclusion, recent developments are clearly pointing in the right direction. A comeback candidate could be BioNxt Solutions. Biotech companies are currently overshadowed by the AI boom, but following recent news flow, BioNxt is emerging as a hot buy—and perhaps even a takeover candidate. A potential beneficiary of peace in the Middle East and the reopening of the Strait of Hormuz could be TUI AG. Even without such geopolitical tailwinds, analysts still see further upside potential. Could gains of 50% be possible?
Read
Commented by André Will-Laudien on May 21st, 2026 | 07:10 CEST
Undervalued – Analysts Turn Their Attention to Life Sciences: Bayer, Vidac Pharma, Novo Nordisk, and Pfizer in Focus
DZ Bank's aggressive price target adjustment for Bayer demonstrates that analysts have recently begun to view the life sciences sector more favourably. The pharmaceutical and agrochemical group's strong start to the year has led to significantly improved prospects, and legal risks are now also viewed as more moderate. Finally, some good news for long-suffering investors in a geopolitically volatile environment. After all, there have not been any major upgrades in the sector for quite some time. When it comes to Novo Nordisk, however, experts remain divided on whether the earnings trend will turn positive again. Cutthroat competition in the weight-loss drug market is intense, putting pressure on margins. Buoyed by industry sentiment, Pfizer also saw its stock rise again. Time for a new tour of the sector. Where are the triggers?
Read
Commented by André Will-Laudien on May 20th, 2026 | 08:05 CEST
Takeover Candidates for 2026! The Life Sciences Sector Is Heating Up: Evotec, BioNxt Solutions, BioNTech, and Formycon in Focus!
In recent months, the stock market has focused primarily on high-tech and defence stocks. While this strategy may have worked well for investors in the short term, it has also pushed several life sciences stocks to levels that some consider overly depressed. The Hamburg-based drug discovery company Evotec has lost around 75% of its market value over the past three years, with similar declines seen at BioNTech, Formycon, and BioNxt Solutions. Yet some pipelines are indeed valuable and backed by years of research. For a buyer with deep pockets, this could represent an attractive opportunity, as much of the costly early-stage work has already been completed. We are looking at a sector that has been unjustly forgotten. Where do opportunities lie for risk-conscious investors?
Read
Commented by Fabian Lorenz on May 19th, 2026 | 07:25 CEST
BUY RECOMMENDATIONS for RENK and Desert Gold! SHOCK for Evotec!
While gold prices are weakening, Desert Gold shares are in a clear uptrend. And if analysts are to be believed, a tenfold increase is possible. Desert Gold is set to become a gold producer in just a few months and generate strong cash flows. And it does not matter whether gold is trading at USD 4,000 or USD 6,000 per ounce. RENK stock has been upgraded to "Buy." Not because the future outlook has improved, but because the price has plummeted. This means the valuation now offers upside potential again. The growth prospects are quite positive. Meanwhile, analysts have recently noted a lack of growth prospects at Evotec. For many, "Project Horizon" focuses too heavily on cost reduction. But growth is precisely what is expected from a biotech company. And now, the restructuring costs are also to be financed through a convertible bond.
Read
Commented by Nico Popp on May 14th, 2026 | 07:50 CEST
Checkmate for Cancer: What Eli Lilly and Bayer Can Learn from Vidac Pharma
Modern medicine is on the cusp of groundbreaking innovations in which the regulation of cellular energy metabolism, known as metabolic correction, is becoming a decisive strategy. While traditional cancer research has relied primarily on the destruction of cells using toxic agents for decades, researchers now recognize that the key to success may lie in the precise control of enzymatic processes. In light of this, value creation is shifting away from the conventional "sledgehammer approach" toward correcting cellular dysregulation. We highlight three exciting companies and focus in particular on metabolism pioneer Vidac Pharma.
Read
Commented by Nico Popp on May 12th, 2026 | 09:10 CEST
Biotech and the Efficiency Revolution: Why the Final Mile Matters Most for Novartis, BioNTech, and BioNxt
While biotech investors long believed that only the discovery of an entirely new molecule could pave the way for a billion-dollar exit, the current market reality paints a far more nuanced picture. Savvy investors and industry analysts are increasingly recognizing that the true bottleneck in modern medicine is no longer the discovery of active ingredients alone. Instead, the strategic focus is shifting toward bioavailability, targeted drug delivery, and improved patient compliance. This transformation is being accelerated by the looming patent cliff, which threatens the pharmaceutical industry with combined annual peak revenues of several hundred billion US dollars by 2030. We take a closer look at the market and highlight emerging opportunities.
Read
Commented by Fabian Lorenz on May 12th, 2026 | 07:10 CEST
SHARE PRICE DROP for Nel ASA and Evotec! SHARE PRICE OPPORTUNITY for HPQ Silicon!
Is HPQ Silicon's stock poised for a revaluation? There are certainly good reasons to think so. Its high-performance batteries have once again impressed. This could signal a significant technological leap forward for applications in drones, defence, mobility, and high-end electronics. Nel ASA's new generation of pressure-driven alkaline electrolyzers is expected to represent such a technological leap. On the stock market, however, the announcement triggered a sell-off. Investors had likely speculated on bigger news following the rally. There is disappointment also at Evotec. The management board provided an optimistic outlook in its Q1 results, but first-quarter revenue and EBITDA were initially underwhelming. Analysts' price targets vary widely.
Read
Commented by Carsten Mainitz on May 8th, 2026 | 07:25 CEST
Take note! The stock market is (still) ignoring key developments at Desert Gold, Evotec, and Mutares!
The past few weeks have been challenging for stock market traders. However, investors should not dwell too long on missed opportunities; they still exist across a wide range of industries and for various reasons. Desert Gold, Evotec, and Mutares currently stand out. These companies have one thing in common: their groundbreaking progress has so far been ignored by the stock market and is only partially reflected in their prices. This opens up lucrative opportunities for forward-thinking investors. Analysts see significant upside potential for all three stocks. Who is leading the race?
Read